Shots:
- The US FDA has approved Dupixent to treat CSU pts (≥12yrs.), who were symptomatic despite H1 antihistamine treatment based on 2 P-III (Study A & C) trials from LIBERTY-CUPID program; regulatory review ongoing in EU & other regions
- Study A & C assessed Dupixent (loading dose then 300mg Q2W; pts weighing <60kg received 200mg) as an add-on therapy vs PBO in 136 & 148 CSU pts (≥6yrs.), incl. biologic-naïve pts, meeting their 1EPs of reduced itch severity & urticaria activity at 24wks.
- Study B did not meet its 1EP but provided additional safety data on Dupixent in 108 pts (≥12yrs.) with inadequate response or intolerance to anti-IgE therapy who remained symptomatic despite antihistamine use; data from Study A & B was published in The JACI
Ref: Regeneron | Image: Regeneron & Sanofi
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
